Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration of Mitomycin C for High-Grade Non–Muscle Invasive Bladder Cancer After BCG Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Sequential Administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of Mitomycin C (MMC) for the Treatment of High-Grade Nonmuscle Invasive Bladder Cancer After BCG Failure
Urol. Oncol 2020 Jul 22;[EPub Ahead of Print], T Juvet, A Mari, K Lajkosz, CJ Wallis, C Kuk, A Erlich, L Krimus, NE Fleshner, GS Kulkarni, AR ZlottaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.